CA
NZ
UK
AU
IND
US
• Edgewise Therapeutics is trading at $42.39, up 0.21% intraday, effectively unchanged with normal volume and no directional institutional conviction.
• ENDRA Life Sciences is down 6.70% intraday at $5.85, consistent with a pattern of opening strength followed by sharp reversal characteristic of low-float medical device names without fresh catalysts.
• enVVeno Medical is showing a gain of 10.93% at $11.37, but the extremely thin trading volume and possible stale execution mean the print should be treated with significant caution.
• Galectin Therapeutics is trading at $4.05, up 3.32% intraday, in a session of steady accumulation without a sharp spike-and-fade, a constructive intraday pattern.
• Ginkgo Bioworks is trading at $10.38, up 6.68% intraday, carried higher by sector-wide re-rating following Merck KGaA's $11.3 billion acquisition of Bio-Techne.
• CapsoVision is trading at $7.22, up 1.83% intraday, recovering from an opening low of $7.09 to near the session high of $7.25 in a clean accumulation pattern.
• Vicarious Surgical Inc. (RBOT) will undergo a change in its financial leadership with the upcoming departure of Chief Financial Officer Sarah Romano.
• CalciMedica (NASDAQ: CALC) receives no regulatory comments after submitting interim safety data from its KOURAGE trial for Auxora in acute kidney injury patients.
• Definium Therapeutics (NASDAQ: DFTX) plans to sell $500 million in common shares and pre‑funded warrants in a public offering.
• HeartBeam (NASDAQ: BEAT) restructures leadership, transitioning to a model led by founder Branislav Vajdic and Executive Chairman Rich Ferrari.
Please wait processing your request...